Compare Keysight Technologies Inc (KEYS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs ResMed Inc. — how do they compare? Keysight Technologies Inc trades at $329.98 (market cap $53.68B), while ResMed Inc. trades at $194.34 (market cap $28.81B). The key difference: Keysight Technologies Inc is the larger of the two by market cap, and ResMed Inc. pays a 1.21% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| KEYS | RMD | |
|---|---|---|
Market Cap | $53.68B | $28.81B |
Sector | Technology | Health |
52-Week High | $373.34 | $293.73 |
52-Week Low | $158.51 | $182.82 |
Enterprise Value | $54.03B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $328.11, up 3.87% today, with strong earnings beats in recent quarters. The stock shows a bearish technical signal despite positive analyst sentiment, with 81% buy ratings and a $396.56 consensus price target. Recent developments include partnerships with the European Space Agency and acquisitions in photonics design, positioning the company for growth in 5G and AI-driven markets.
Outlook remains positive due to robust fundamentals and strategic expansions, but high valuation multiples and technical weakness pose risks. Revenue is projected to grow to $6.1B in 2026, with net income margin improving to 17.31%. Investors should weigh strong profitability against elevated P/E of 50.58 and current bearish momentum.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
